What is VolitionRx?
VolitionRx is a multinational epigenetic company dedicated to transforming patient outcomes through the science of epigenetics. The firm specializes in the creation of simple, non-invasive blood tests designed to detect and monitor diseases, including various forms of cancer and conditions related to NETosis, such as sepsis. By leveraging its unique diagnostic platform, VolitionRx aims to provide healthcare providers with actionable insights that facilitate earlier intervention and more precise treatment monitoring. The company operates at the intersection of molecular biology and clinical diagnostics, positioning itself as a critical innovator in the effort to improve survival rates and reduce the burden of chronic and acute diseases on global healthcare systems.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $11.3M across 4 funding rounds:
Private Equity
$1.5M
Debt
$5.5M
Stock/Share Issuance
$2M
Other Financing Round
$2.3M
Private Equity (2022): $1.5M with participation from Namur Invest Capital Risk
Debt (2023): $5.5M, investors not publicly disclosed
Stock/Share Issuance (2026): $2M supported by The Lind Partners
Other Financing Round (2026): $2.3M featuring Wallonie Entreprendre and Namur Invest
Key Investors in VolitionRx
The Lind Partners
The Lind Partners is an institutional fund manager and leading provider of growth capital to small- and mid-cap companies, specializing in flexible financing solutions for publicly traded firms.
Wallonie Entreprendre
Wallonie Entreprendre is a regional investment entity focused on fostering economic development and supporting innovative business projects within the Wallonia region of Belgium.
Namur Invest
Namur Invest is a public-private partnership that provides tailored financing solutions, including equity and loans, to support the growth and innovation of businesses in the Namur province.
What's next for VolitionRx?
With the successful closure of this major strategic investment, VolitionRx is well-positioned to accelerate its commercialization strategy and deepen its clinical research initiatives. The influx of capital will likely be directed toward scaling the production of its diagnostic assays and expanding its market reach into key international territories. Furthermore, the company is expected to prioritize the validation of its technology across broader patient populations, potentially unlocking new revenue streams through strategic partnerships and regulatory milestones. As VolitionRx moves into this next phase of growth, the focus remains on maintaining its competitive edge in the epigenetic diagnostics market while delivering high-value, life-saving solutions to the clinical community.
See full VolitionRx company page
